Amy L. Burroughs - 30 Jan 2025 Form 4 Insider Report for Terns Pharmaceuticals, Inc. (TERN)

Role
Chief Executive Officer, Director
Signature
/s/ David Strauss, as Attorney-in-Fact for Amy L. Burroughs
Issuer symbol
TERN
Transactions as of
30 Jan 2025
Net transactions value
+$2,606
Form type
4
Filing time
03 Feb 2025, 19:25:48 UTC
Previous filing
09 Dec 2024
Next filing
30 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TERN Common Stock Purchase $2,606 +510 +2.7% $5.11 19,609 30 Nov 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TERN Stock Option (Right to Buy) Award $0 +1,075,000 $0.000000 1,075,000 30 Jan 2025 Common Stock 1,075,000 $4.64 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes an additional 510 shares acquired by the reporting person under the Issuer's 2021 Employee Stock Purchase Plan on November 30, 2024 that was not previously reported on the reporting person's Form 4 filed on December 9, 2024 due to an administrative error.
F2 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.